Molecular Reprogramming of Cardiac Fibroblasts into Induced Cardiomyocytes: Progress and Pitfalls

Background: Direct cardiac reprogramming—the molecular conversion of resident fibroblasts into induced cardiomyocytes (iCMs)—has emerged as a promising strategy to regenerate injured myocardium and reverse fibrotic remodeling after cardiac injury. This approach bypasses the need for exogenous stem cells or transplantation and leverages in situ reprogramming to restore contractile tissue. Seminal studies have identified key transcription factor combinations, including Gata4, Mef2c, and Tbx5 (GMT), capable of initiating reprogramming in vitro and in vivo. However, translational barriers remain, including low reprogramming efficiency, incomplete maturation, and safety concerns. Methods and Results: This review synthesizes recent advances in cardiac reprogramming, focusing on transcriptomic, epigenomic, and chromatin accessibility changes during fibroblast-to-cardiomyocyte conversion. We examine enhancements to the GMT cocktail via addition of factors such as Hand2, Myocd, and microRNAs, as well as small molecules that modulate epigenetic regulators like HDACs, BRD4, and DNMTs. Studies using single-cell RNA sequencing and ATAC-seq reveal distinct intermediate states and identify barriers such as fibroblast identity retention and lineage-inappropriate gene activation. Epigenetic memory and cell-intrinsic resistance appear to be major obstacles limiting the transition to fully functional cardiomyocyte states. Strategies including 3D culture systems, metabolic reprogramming, and combinatorial delivery platforms have improved iCM yield and electrophysiological function. Moreover, recent work demonstrates that immune microenvironment and mechanical cues from the extracellular matrix play essential roles in reprogramming outcomes. Nonetheless, challenges persist, including immunogenicity, arrhythmogenic potential, off-target effects, and lack of scalable, safe delivery systems. Conclusion: Molecular reprogramming of cardiac fibroblasts into iCMs represents a compelling regenerative strategy with the potential to transform post-infarction therapy.